Cellular mechanism for impaired hepatitis c virus clearance by interferon associated with IFNL3 gene polymorphisms relates to intrahepatic interferon-λ expression

American Journal of Pathology

Volumn 186, Issue 4, 2016, Pages 938-951

  Ferraris, Pauline ^a   Chandra, Partha K ^a   Panigrahi, Rajesh ^a   Aboulnasr, Fatma ^a   Chava, Srinivas ^a   Kurt, Ramazan ^a   Pawlotsky, Jean Michel ^b   Wilkens, Ludwig ^c   Osterlund, Pamela ^d   Hartmann, Rune ^e   Balart, Luis A ^a   Wu, Tong ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b INSERM U955   (France)

^c UNIVERSITY OF BERN   (Switzerland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERFERON; INTERFERON L3; INTERLEUKIN 28B; INTERLEUKIN 29; JANUS KINASE; PEGINTERFERON LAMBDA; STAT PROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRAL CLEARANCE; WESTERN BLOTTING; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; LIVER TUMOR; METABOLISM; VIROLOGY;

ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84962538388     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2015.11.027     Document Type: Article

References (50)

1. D. Lavanchy The global burden of hepatitis C Liver Int 29 Suppl 1 2009 74 81
2. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consens State Sci Statements 19 2002 1 46
3. D.L. Thomas, C.L. Thio, M.P. Martin, Y. Qi, D. Ge, C. O'Huigin, J. Kidd, K. Kidd, S.I. Khakoo, G. Alexander, J.J. Goedert, G.D. Kirk, S.M. Donfield, H.R. Rosen, L.H. Tobler, M.P. Busch, J.G. McHutchison, D.B. Goldstein, and M. Carrington Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
4. J.D. Yang, and L.R. Roberts Hepatocellular carcinoma: a global view Nat Rev Gastroenterol Hepatol 7 2010 448 458
5. K. Matsuura, T. Watanabe, and Y. Tanaka Role of IL28B for chronic hepatitis C treatment toward personalized medicine J Gastroenterol Hepatol 29 2014 241 249
6. R.P. Donnelly, H. Dickensheets, and T.R. O'Brien Interferon-lambda and therapy for chronic hepatitis C virus infection Trends Immunol 32 2011 443 450
7. S. Dash, R. Prabhu, S. Hazari, F. Bastian, R. Garry, W. Zou, S. Haque, V. Joshi, F.G. Regenstein, and S.N. Thung Interferons alpha, beta, gamma each inhibit hepatitis C virus replication at the level of internal ribosome entry site-mediated translation Liver Int 25 2005 580 594
8. T.J. Liang, and M.G. Ghany Current and future therapies for hepatitis C virus infection N Engl J Med 368 2013 1907 1917
9. A. Rauch, Z. Kutalik, P. Descombes, T. Cai, J. Di Iulio, T. Mueller, M. Bochud, M. Battegay, E. Bernasconi, J. Borovicka, S. Colombo, A. Cerny, J.F. Dufour, H. Furrer, H.F. Gunthard, M. Heim, B. Hirschel, R. Malinverni, D. Moradpour, B. Mullhaupt, A. Witteck, J.S. Beckmann, T. Berg, S. Bergmann, F. Negro, A. Telenti, and P.Y. Bochud Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345 1345 e1-7
10. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, M. Sulkowski, J.G. McHutchison, and D.B. Goldstein Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
11. Y. Tanaka, N. Nishida, M. Sugiyama, M. Kurosaki, K. Matsuura, N. Sakamoto, M. Nakagawa, M. Korenaga, K. Hino, S. Hige, Y. Ito, E. Mita, E. Tanaka, S. Mochida, Y. Murawaki, M. Honda, A. Sakai, Y. Hiasa, S. Nishiguchi, A. Koike, I. Sakaida, M. Imamura, K. Ito, K. Yano, N. Masaki, F. Sugauchi, N. Izumi, K. Tokunaga, and M. Mizokami Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
12. V. Suppiah, M. Moldovan, G. Ahlenstiel, T. Berg, M. Weltman, M.L. Abate, M. Bassendine, U. Spengler, G.J. Dore, E. Powell, S. Riordan, D. Sheridan, A. Smedile, V. Fragomeli, T. Muller, M. Bahlo, G.J. Stewart, D.R. Booth, and J. George IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
13. L. Prokunina-Olsson, B. Muchmore, W. Tang, R.M. Pfeiffer, H. Park, H. Dickensheets, D. Hergott, P. Porter-Gill, A. Mumy, I. Kohaar, S. Chen, N. Brand, M. Tarway, L. Liu, F. Sheikh, J. Astemborski, H.L. Bonkovsky, B.R. Edlin, C.D. Howell, T.R. Morgan, D.L. Thomas, B. Rehermann, R.P. Donnelly, and T.R. O'Brien A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Nat Genet 45 2013 164 171
14. T.W. Chu, R. Kulkarni, E.J. Gane, S.K. Roberts, C. Stedman, P.W. Angus, B. Ritchie, X.Y. Lu, D. Ipe, U. Lopatin, S. Germer, V.A. Iglesias, R. Elston, P.F. Smith, and N.S. Shulman Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C Gastroenterology 142 2012 790 795
15. E.G. Meissner, D. Bon, L. Prokunina-Olsson, W. Tang, H. Masur, T.R. O'Brien, E. Herrmann, S. Kottilil, and A. Osinusi IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin J Infect Dis 209 2014 1700 1704
16. E.G. Meissner, D. Wu, A. Osinusi, D. Bon, K. Virtaneva, D. Sturdevant, S. Porcella, H. Wang, E. Herrmann, J. McHutchison, A.F. Suffredini, M. Polis, S. Hewitt, L. Prokunina-Olsson, H. Masur, A.S. Fauci, and S. Kottilil Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome J Clin Invest 124 2014 3352 3363
17. T.R. Morgan, and T.R. O'Brien IL28B-genotype testing now and in the era of direct-acting antiviral agents Clin Gastroenterol Hepatol 9 2011 293 294
18. X. Shi, Y. Pan, M. Wang, D. Wang, W. Li, T. Jiang, P. Zhang, X. Chi, Y. Jiang, Y. Gao, J. Zhong, B. Sun, D. Xu, J. Jiang, and J. Niu IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population PLoS One 7 2012 e37054
19. B. Langhans, B. Kupfer, I. Braunschweiger, S. Arndt, W. Schulte, H.D. Nischalke, J. Nattermann, J. Oldenburg, T. Sauerbruch, and U. Spengler Interferon-lambda serum levels in hepatitis C J Hepatol 54 2011 859 865
20. A. Dolganiuc, K. Kodys, C. Marshall, B. Saha, S. Zhang, S. Bala, and G. Szabo Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells PLoS One 7 2012 e44915
21. S. Zhang, K. Kodys, K. Li, and G. Szabo Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection Gastroenterology 144 2013 414 425.e7
22. A.P. McFarland, S.M. Horner, A. Jarret, R.C. Joslyn, E. Bindewald, B.A. Shapiro, D.A. Delker, C.H. Hagedorn, M. Carrington, M. Gale Jr., and R. Savan The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs Nat Immunol 15 2014 72 79
23. P.K. Chandra, L. Bao, K. Song, F.M. Aboulnasr, D.P. Baker, N. Shores, W.C. Wimley, S. Liu, C.H. Hagedorn, S.Y. Fuchs, T. Wu, L.A. Balart, and S. Dash HCV infection selectively impairs type I but not type III IFN signaling Am J Pathol 184 2014 214 229
24. R. Panigrahi, S. Hazari, S. Chandra, P.K. Chandra, S. Datta, R. Kurt, C.E. Cameron, Z. Huang, H. Zhang, R.F. Garry, L.A. Balart, and S. Dash Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation PLoS One 8 2013 e72791
25. R. Panigrahi, P.K. Chandra, P. Ferraris, R. Kurt, K. Song, R.F. Garry, K. Reiss, I.R. Coe, T. Furihata, L.A. Balart, T. Wu, and S. Dash Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1 J Virol 89 2014 626 642
26. P.K. Chandra, F. Gunduz, S. Hazari, R. Kurt, R. Panigrahi, B. Poat, D. Bruce, A.J. Cohen, H.E. Bohorquez, I. Carmody, G. Loss, L.A. Balart, T. Wu, and S. Dash Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis PLoS One 9 2014 e108616
27. B. Israelow, C.M. Narbus, M. Sourisseau, and M.J. Evans HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection Hepatology 60 2014 1170 1179
28. P.I. Osterlund, T.E. Pietila, V. Veckman, S.V. Kotenko, and I. Julkunen IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes J Immunol 179 2007 3434 3442
29. O.J. Hamming, E. Terczynska-Dyla, G. Vieyres, R. Dijkman, S.E. Jorgensen, H. Akhtar, P. Siupka, T. Pietschmann, V. Thiel, and R. Hartmann Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses EMBO J 32 2013 3055 3065
30. S. Bibert, T. Roger, T. Calandra, M. Bochud, A. Cerny, N. Semmo, F.H. Duong, T. Gerlach, R. Malinverni, D. Moradpour, F. Negro, B. Mullhaupt, P.Y. Bochud Swiss Hepatitis C Cohort Study IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction J Exp Med 210 2013 1109 1116
31. P. Pinzani, F. Salvianti, R. Cascella, D. Massi, V. De Giorgi, M. Pazzagli, and C. Orlando Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients Clin Chim Acta 411 2010 1319 1324
32. M. Sugano, Y. Hayashi, S. Yoon, M. Kinoshita, T. Ninomiya, K. Ohta, H. Itoh, and M. Kasuga Quantitation of hepatitis C viral RNA in liver and serum samples using competitive polymerase chain reaction J Clin Pathol 48 1995 820 825
33. C.B. Bigger, B. Guerra, K.M. Brasky, G. Hubbard, M.R. Beard, B.A. Luxon, S.M. Lemon, and R.E. Lanford Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees J Virol 78 2004 13779 13792
34. A.J. Sadler, and B.R. Williams Interferon-inducible antiviral effectors Nat Rev Immunol 8 2008 559 568
35. M. Pai, R. Prabhu, A. Panebra, S. Nangle, S. Haque, F. Bastian, R. Garry, K. Agrawal, S. Goodbourn, and S. Dash Activation of interferon-stimulated response element in huh-7 cells replicating hepatitis C virus subgenomic RNA Intervirology 48 2005 301 311
36. M. Murakawa, Y. Asahina, M. Nakagawa, N. Sakamoto, S. Nitta, A. Kusano-Kitazume, T. Watanabe, F. Kawai-Kitahata, S. Otani, M. Taniguchi, F. Goto, Y. Nishimura-Sakurai, Y. Itsui, S. Azuma, S. Kakinuma, and M. Watanabe Impaired induction of interleukin 28B and expression of interferon lambda 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C J Gastroenterol Hepatol 30 2015 1075 1084
37. B. Poat, S. Hazari, P.K. Chandra, F. Gunduz, X. Alvarez, L.A. Balart, R.F. Garry, and S. Dash Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication Virol J 7 2010 265
38. D. Svetlikova, P. Kabat, A. Ohradanova, J. Pastorek, and T. Betakova Influenza A virus replication is inhibited in IFN-lambda2 and IFN-lambda3 transfected or stimulated cells Antiviral Res 88 2010 329 333
39. T.J. Urban, A.J. Thompson, S.S. Bradrick, J. Fellay, D. Schuppan, K.D. Cronin, L. Hong, A. McKenzie, K. Patel, K.V. Shianna, J.G. McHutchison, D.B. Goldstein, and N. Afdhal IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C Hepatology 52 2010 1888 1896
40. M. Honda, T. Shirasaki, T. Shimakami, A. Sakai, R. Horii, K. Arai, T. Yamashita, Y. Sakai, T. Yamashita, H. Okada, K. Murai, M. Nakamura, E. Mizukoshi, and S. Kaneko Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes Hepatology 59 2014 828 838
41. M.T. Dill, F.H. Duong, J.E. Vogt, S. Bibert, P.Y. Bochud, L. Terracciano, A. Papassotiropoulos, V. Roth, and M.H. Heim Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C Gastroenterology 140 2011 1021 1031
42. T. Asselah, I. Bieche, S. Narguet, A. Sabbagh, I. Laurendeau, M.P. Ripault, N. Boyer, M. Martinot-Peignoux, D. Valla, M. Vidaud, and P. Marcellin Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C Gut 57 2008 516 524
43. L. Chen, I. Borozan, J. Feld, J. Sun, L.L. Tannis, C. Coltescu, J. Heathcote, A.M. Edwards, and I.D. McGilvray Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection Gastroenterology 128 2005 1437 1444
44. M. Honda, A. Sakai, T. Yamashita, Y. Nakamoto, E. Mizukoshi, Y. Sakai, T. Yamashita, M. Nakamura, T. Shirasaki, K. Horimoto, Y. Tanaka, K. Tokunaga, M. Mizokami, S. Kaneko Hokuriku Liver Study Group Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2010 499 509
45. F.H. Duong, G. Trincucci, T. Boldanova, D. Calabrese, B. Campana, I. Krol, S.C. Durand, L. Heydmann, M.B. Zeisel, T.F. Baumert, and M.H. Heim IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies J Exp Med 211 2014 857 868
46. D. Booth, and J. George Loss of function of the new interferon IFN-lambda4 may confer protection from hepatitis C Nat Genet 45 2013 119 120
47. Y. Asahina, K. Tsuchiya, M. Muraoka, K. Tanaka, Y. Suzuki, N. Tamaki, Y. Hoshioka, Y. Yasui, T. Katoh, T. Hosokawa, K. Ueda, H. Nakanishi, J. Itakura, Y. Takahashi, M. Kurosaki, N. Enomoto, S. Nitta, N. Sakamoto, and N. Izumi Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response Hepatology 55 2012 20 29
48. Z. Makowska, F.H. Duong, G. Trincucci, D.F. Tough, and M.H. Heim Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo Hepatology 53 2011 1154 1163
49. U. Garaigorta, and F.V. Chisari Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation Cell Host Microbe 6 2009 513 522
50. E. Terczynska-Dyla, S. Bibert, F.H. Duong, I. Krol, S. Jorgensen, E. Collinet, Z. Kutalik, V. Aubert, A. Cerny, L. Kaiser, R. Malinverni, A. Mangia, D. Moradpour, B. Mullhaupt, F. Negro, R. Santoro, D. Semela, N. Semmo Swiss Hepatitis C Cohort Study Group M.H. Heim, P.Y. Bochud, and R. Hartmann Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes Nat Commun 5 2014 5699